## Noemi Pavo

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8797512/publications.pdf

Version: 2024-02-01

302126
39
g-index
2002
2983
citing authors

#	Article	IF	CITATIONS
1	Soluble neprilysin and survival in critically ill patients. ESC Heart Failure, 2022, , .	3.1	2
2	Circulating dipeptidyl peptidase (cDPP3)—A marker for endâ€stage heart failure?. Journal of Internal Medicine, 2022, 291, 886-890.	6.0	2
3	Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction. Diagnostics, 2022, 12, 444.	2.6	8
4	Guideline directed <i>medical</i> therapy and reduction of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2022, 23, 755-764.	1.2	9
5	Malnutrition outweighs the effect of the obesity paradox. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1477-1486.	7.3	12
6	Cell-Based HIF1 $\hat{l}\pm$ Gene Therapy Reduces Myocardial Scar and Enhances Angiopoietic Proteome, Transcriptomic and miRNA Expression in Experimental Chronic Left Ventricular Dysfunction. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	1
7	Increased concentrations of bioactive adrenomedullin subsequently to angiotensinâ€receptor/neprilysinâ€inhibitor treatment in chronic systolic heart failure. British Journal of Clinical Pharmacology, 2021, 87, 916-924.	2.4	13
8	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2021, 34, 13-19.	2.8	19
9	Secondary mitral regurgitationâ€"Insights from microRNA assessment. European Journal of Clinical Investigation, 2021, 51, e13381.	3.4	4
10	Novel Identified Circular Transcript of RCAN2, circ-RCAN2, Shows Deviated Expression Pattern in Pig Reperfused Infarcted Myocardium and Hypoxic Porcine Cardiac Progenitor Cells In Vitro. International Journal of Molecular Sciences, 2021, 22, 1390.	4.1	4
11	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 34.	6.8	20
12	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	3.1	3
13	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	2.8	18
14	The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor. Journal of Neuro-Oncology, 2021, 153, 497-505.	2.9	4
15	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ, The, 2021, 373, n1421.	6.0	32
16	Principal Morphomic and FunctionalÂComponents of Secondary MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2021, 14, 2288-2300.	5.3	26
17	Reply. Journal of the American College of Cardiology, 2021, 78, 543-544.	2.8	0
18	Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1577-1596.	7.1	23

#	Article	IF	CITATIONS
19	Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data. Cardio-Oncology, 2021, 7, 35.	1.7	9
20	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. Frontiers in Cardiovascular Medicine, 2021, 8, 725903.	2.4	12
21	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	4.1	5
22	Gender differences in examination behavior of 4th grade medical students. Wiener Klinische Wochenschrift, 2021, , 1.	1.9	1
23	Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovascular Research, 2020, 116, 970-982.	3.8	32
24	Large Animal Models of Cell-Free Cardiac Regeneration. Biomolecules, 2020, 10, 1392.	4.0	15
25	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. Journal of Personalized Medicine, 2020, 10, 233.	2.5	1
26	Prescription Bias in the Treatment of Chronic Systolic Heart Failure. Annals of Internal Medicine, 2020, 172, 70.	3.9	2
27	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	4.1	9
28	Circular RNAs in Cardiac Regeneration: Cardiac Cell Proliferation, Differentiation, Survival, and Reprogramming. Frontiers in Physiology, 2020, 11, 580465.	2.8	13
29	Comparative Effect of MSC Secretome to MSC Co-culture on Cardiomyocyte Gene Expression Under Hypoxic Conditions in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 502213.	4.1	5
30	Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. Journal of the American Heart Association, 2020, 9, e015071.	3.7	5
31	Multimarker Approach to Identify Patients with Coronary Artery Disease at High Risk for Subsequent Cardiac Adverse Events: The Multi-Biomarker Study. Biomolecules, 2020, 10, 909.	4.0	3
32	Increased resting heart rate and prognosis in treatmentâ€naÃ⁻ve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	7.1	23
33	Quantitative Hybrid Cardiac [18F]FDG-PET-MRI Images for Assessment of Cardiac Repair by Preconditioned Cardiosphere-Derived Cells. Molecular Therapy - Methods and Clinical Development, 2020, 18, 354-366.	4.1	9
34	Early Elevation of Systemic Plasma Clusterin after Reperfused Acute Myocardial Infarction in a Preclinical Porcine Model of Ischemic Heart Disease. International Journal of Molecular Sciences, 2020, 21, 4591.	4.1	4
35	The inflammationâ€based modified Glasgow prognostic score is associated with survival in stable heart failure patients. ESC Heart Failure, 2020, 7, 654-662.	3.1	23
36	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. European Heart Journal, 2020, 41, 2799-2810.	2.2	45

#	Article	IF	CITATIONS
37	Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries. Histology and Histopathology, 2020, 35, 653-663.	0.7	0
38	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1728-1737.	5.3	21
39	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. European Heart Journal Cardiovascular Imaging, 2019, 21, 168-174.	1.2	5
40	Disproportionate Functional MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 2088-2090.	5.3	32
41	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. European Journal of Clinical Investigation, 2019, 49, e13159.	3.4	10
42	GDFâ€15 in solid vs nonâ€solid treatmentâ€naÃ⁻ve malignancies. European Journal of Clinical Investigation, 2019, 49, e13168.	3.4	10
43	Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF). Frontiers in Cardiovascular Medicine, 2019, 6, 117.	2.4	35
44	Reply. Journal of the American College of Cardiology, 2019, 74, 1845-1847.	2.8	3
45	Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection. International Journal of Molecular Sciences, 2019, 20, 344.	4.1	10
46	A Unifying Concept for the QuantitativeÂAssessment of SecondaryÂMitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2506-2517.	2.8	86
47	Effect of Ischemic Preconditioning and Postconditioning on Exosome-Rich Fraction microRNA Levels, in Relation with Electrophysiological Parameters and Ventricular Arrhythmia in Experimental Closed-Chest Reperfused Myocardial Infarction. International Journal of Molecular Sciences, 2019, 20, 2140.	4.1	28
48	Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure. European Journal of Heart Failure, 2019, 21, 537-539.	7.1	4
49	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-na $\tilde{A}$ -ve cancer patients. Scientific Reports, 2019, 9, 2554.	3.3	18
50	Natural History of FunctionalÂTricuspidÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 389-397.	5.3	102
51	Natural history of bivalvular functional regurgitation. European Heart Journal Cardiovascular Imaging, 2019, 20, 565-573.	1.2	9
52	Acute HIV Infection Results in Subclinical Inflammatory Cardiomyopathy. Journal of Infectious Diseases, 2018, 218, 466-470.	4.0	12
53	Nâ€ŧerminal Bâ€ŧype natriuretic peptide (NTâ€proBNP) is associated with disease severity in multiple myeloma. European Journal of Clinical Investigation, 2018, 48, e12905.	3.4	8
54	Evolution of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2018, 19, 622-629.	1.2	40

#	Article	IF	Citations
55	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. European Heart Journal, 2018, 39, 39-46.	2.2	261
56	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clinical Chemistry, 2018, 64, 597-608.	3.2	52
57	Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS ONE, 2018, 13, e0206830.	2.5	14
58	Transcatheter aortic valve replacement (TAVR) leads to an increase in the subendocardial viability ratio assessed by pulse wave analysis. PLoS ONE, 2018, 13, e0207537.	2.5	14
59	Lipid profile and longâ€term outcome in premature myocardial infarction. European Journal of Clinical Investigation, 2018, 48, e13008.	3.4	18
60	Polyunsaturated fatty acids supplementation impairs antiâ€oxidant highâ€density lipoprotein function in heart failure. European Journal of Clinical Investigation, 2018, 48, e12998.	3.4	9
61	Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery. Frontiers in Bioengineering and Biotechnology, 2018, 6, 35.	4.1	14
62	Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Scientific Reports, 2017, 7, 43958.	3.3	33
63	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. International Journal of Cardiology, 2017, 240, 37-42.	1.7	15
64	In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature. Journal of Translational Medicine, 2017, 15, 67.	4.4	29
65	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. Journal of Translational Medicine, 2017, 15, 202.	4.4	33
66	Impact of HIV infection and antiretroviral treatment on N-terminal prohormone of brain natriuretic peptide as surrogate of myocardial function. Aids, 2017, 31, 395-400.	2.2	5
67	Subclinical involvement of the liver is associated with prognosis in treatment $na\tilde{A}$ ve cancer patients. Oncotarget, 2017, 8, 81250-81260.	1.8	15
68	Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget, 2017, 8, 67227-67240.	1.8	5
69	GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes. Clinical Chemistry, 2016, 62, 1612-1620.	3.2	26
70	Short structured feedback training is equivalent to a mechanical feedback device in two-rescuer BLS: a randomised simulation study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2016, 24, 70.	2.6	19
71	Soluble galectinâ€3 is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 386-391.	3.4	23
72	Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 2912-2914.	2.8	24

#	Article	IF	CITATIONS
73	Molecular Imaging of Angiogenesis in Cardiac Regeneration. Current Cardiovascular Imaging Reports, 2016, 9, 27.	0.6	17
74	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 89-93.	7.1	43
75	Genderâ€related differences in elderly patients with myocardial infarction in a European Centre. European Journal of Clinical Investigation, 2016, 46, 60-69.	3.4	7
76	Coating of intravascular balloon with paclitaxel prevents constrictive remodeling of the dilated porcine femoral artery due to inhibition of intimal and media fibrosis. Journal of Materials Science: Materials in Medicine, 2016, 27, 131.	3.6	7
77	Inhibition of CD34+ cell migration by matrix metalloproteinase-2 during acute myocardial ischemia, counteracted by ischemic preconditioning. F1000Research, 2016, 5, 2739.	1.6	6
78	Long-Term Outcome of Combined (Percutaneous Intramyocardial and Intracoronary) Application of Autologous Bone Marrow Mononuclear Cells Post Myocardial Infarction: The 5-Year MYSTAR Study. PLoS ONE, 2016, 11, e0164908.	2.5	4
79	Multimodality imaging of a primary cardiac diffuse large B-cell lymphoma:. European Heart Journal Cardiovascular Imaging, 2015, 16, 909-909.	1.2	4
80	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart, 2015, 101, 1874-1880.	2.9	181
81	Preclinical randomised safety, efficacy and physiologic study of the silicon dioxide inert-coated Axetis and bare metal stent: short-, mid- and long-term outcome. EuroIntervention, 2015, 11, 433-441.	3.2	4
82	Comparison of NOGA Endocardial Mapping and Cardiac Magnetic Resonance Imaging for Determining Infarct Size and Infarct Transmurality for Intramyocardial Injection Therapy Using Experimental Data. PLoS ONE, 2014, 9, e113245.	2.5	11
83	On-Line Visualization of Ischemic Burden During Repetitive Ischemia/Reperfusion. JACC: Cardiovascular Imaging, 2014, 7, 956-958.	5.3	3
84	Cell therapy for human ischemic heart diseases: Critical review and summary of the clinical experiences. Journal of Molecular and Cellular Cardiology, 2014, 75, 12-24.	1.9	75
85	Long-acting beneficial effect of percutaneously intramyocardially delivered secretome of apoptotic peripheral blood cells on porcine chronic ischemic left ventricular dysfunction. Biomaterials, 2014, 35, 3541-3550.	11.4	44
86	Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thrombosis and Haemostasis, 2010, 104, 376-384.	3.4	31